Malignant Gastrointestinal Obstruction: Options for Decompression and Nutrition

Abstract

Malignant bowel obstruction (MBO) is a relatively common condition affecting patients with advanced malignancy. Therapeutic interventions should be aimed at maintaining quality of life. Given the lack of prospective controlled studies in this patient population, patient management is often based on local practice patterns and anecdotal experience. To foster a collaborative approach among the members of the patient care team involving internal medicine, oncology, palliative care, clinical nutrition, surgery, gastroenterology, and interventional radiology physicians, it is important to improve our understanding of MBO. The purpose of this article is to describe the clinical presentation, pathophysiology, as well as medical, surgical, and nonsurgical palliative options available to patients with MBO for purposes of decompression and nutrition.

Keywords

malignant bowel obstruction - decompression - nutrition

Publikationsverlauf

Eingereicht: 11. Mai 2020

Angenommen: 30. Juli 2020

Artikel online veröffentlicht:
30. September 2020

• References

• 1 Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res 2012; 4: 159-169
• 2 Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 1993; 7 (04) 295-299
• 3 Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer 2008; 44 (08) 1105-1115
• 4 Miller G, Boman J, Shrier I, Gordon PH. Small-bowel obstruction secondary to malignant disease: an 11-year audit. Can J Surg 2000; 43 (05) 353-358
• 5 Tuca A, Roca R, Sala C. et al. Efficacy of granisetron in the antiemetic control of nonsurgical intestinal obstruction in advanced cancer: a phase II clinical trial. J Pain Symptom Manage 2009; 37 (02) 259-270
• 6 Laval G, Arvieux C, Stefani L, Villard ML, Mestrallet JP, Cardin N. Protocol for the treatment of malignant inoperable bowel obstruction: a prospective study of 80 cases at Grenoble University Hospital Center. J Pain Symptom Manage 2006; 31 (06) 502-512
• 7 Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol 2001; 8 (08) 632-637
• 8 Taourel P, Kessler N, Lesnik A, Pujol J, Morcos L, Bruel JM. Helical CT of large bowel obstruction. Abdom Imaging 2003; 28 (02) 267-275
• 9 Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer 1993; 72 (05) 1631-1636
• 10 Hofmann B, Håheim LL, Søreide JA. Ethics of palliative surgery in patients with cancer. Br J Surg 2005; 92 (07) 802-809
• 11 Tattersall MH, Butow PN, Clayton JM. Insights from cancer patient communication research. Hematol Oncol Clin North Am 2002; 16 (03) 731-743
• 12 Bennett MI, Livingstone HJ, Costello P, Allen KR, Degg TJ. Symptom scores, serotonin and 5-hydroxyindole acetic acid levels in cancer patients with and without bowel obstruction. Palliat Med 2007; 21 (02) 157-159
• 13 Jiménez-García A, Balongo-García R, Alconero FF. et al. Intestinal wall damage in simple ileus in rabbits: immune-modulator role of somatostatin. Hepatogastroenterology 2004; 51 (58) 1030-1036
• 14 Goyal RK, Hirano I. The enteric nervous system. N Engl J Med 1996; 334 (17) 1106-1115
• 15 Hanks GW, Conno F, Cherny N. Expert Working Group of the Research Network of the European Association for Palliative Care. et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84 (05) 587-593
• 16 Tassinari D, Sartori S, Tamburini E. et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care 2009; 25 (03) 172-180
• 17 Pothuri B, Guirguis A, Gerdes H, Barakat RR, Chi DS. The use of colorectal stents for palliation of large-bowel obstruction due to recurrent gynecologic cancer. Gynecol Oncol 2004; 95 (03) 513-517
• 18 Fainsinger RL, Spachynski K, Hanson J, Bruera E. Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage 1994; 9 (01) 12-18
• 19 Ventafridda V, Ripamonti C, Caraceni A, Spoldi E, Messina L, De Conno F. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 1990; 76 (04) 389-393
• 20 Mercadante S. Bowel obstruction in home-care cancer patients: 4 years experience. Support Care Cancer 1995; 3 (03) 190-193
• 21 De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage 1991; 6 (08) 484-486
• 22 Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182 (5A): 11S-18S
• 23 Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig Dis 2006; 24 (1–2): 105-112
• 24 Davis MP. The opioid bowel syndrome: a review of pathophysiology and treatment. J Opioid Manag 2005; 1 (03) 153-161
• 25 Farmer AD, Holt CB, Downes TJ, Ruggeri E, Del Vecchio S, De Giorgio R. Pathophysiology, diagnosis, and management of opioid-induced constipation. Lancet Gastroenterol Hepatol 2018; 3 (03) 203-212
• 26 Müller-Lissner S, Bassotti G, Coffin B. et al. Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med 2017; 18 (10) 1837-1863
• 27 Yuan CS, Doshan H, Charney MR. et al. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 2005; 45 (05) 538-546
• 28 Mackey AC, Green L, Greene P, Avigan M. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage 2010; 40 (01) e1-e3
• 29 Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 2000; 8 (03) 188-191
• 30 Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 2000; 19 (01) 23-34
• 31 Saxby C, Ackroyd R, Callin S, Mayland C, Kite S. How should we measure emesis in palliative care?. Palliat Med 2007; 21 (05) 369-383
• 32 Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77 (04) 371-383
• 33 Hisanaga T, Shinjo T, Morita T. et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol 2010; 40 (08) 739-745
• 34 Higashi H, Shida H, Ban K. et al. Factors affecting successful palliative surgery for malignant bowel obstruction due to peritoneal dissemination from colorectal cancer. Jpn J Clin Oncol 2003; 33 (07) 357-359
• 35 Legendre H, Vanhuyse F, Caroli-Bosc FX, Pector JC. Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction. Eur J Surg Oncol 2001; 27 (04) 364-367
• 36 Englert ZP, White MA, Fitzgerald TL, Vadlamudi A, Zervoudakis G, Zervos EE. Surgical management of malignant bowel obstruction: at what price palliation?. Am Surg 2012; 78 (06) 647-652
• 37 Turnbull AD, Guerra J, Starnes HF. Results of surgery for obstructing carcinomatosis of gastrointestinal, pancreatic, or biliary origin. J Clin Oncol 1989; 7 (03) 381-386
• 38 Lau PW, Lorentz TG. Results of surgery for malignant bowel obstruction in advanced, unresectable, recurrent colorectal cancer. Dis Colon Rectum 1993; 36 (01) 61-64
• 39 van Ooijen B, van der Burg ME, Planting AS, Siersema PD, Wiggers T. Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet 1993; 176 (05) 469-474
• 40 Jong P, Sturgeon J, Jamieson CG. Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer. Can J Surg 1995; 38 (05) 454-457
• 41 Bais JM, Schilthuis MS, Slors JF, Lammes FB. Intestinal obstruction in patients with advanced ovarian cancer. Int J Gynecol Cancer 1995; 5 (05) 346-350
• 42 Pothuri B, Vaidya A, Aghajanian C, Venkatraman E, Barakat RR, Chi DS. Palliative surgery for bowel obstruction in recurrent ovarian cancer:an updated series. Gynecol Oncol 2003; 89 (02) 306-313
• 43 Chi DS, Phaëton R, Miner TJ. et al. A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist 2009; 14 (08) 835-839
• 44 Kolomainen DF, Daponte A, Barton DP. et al. Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). Gynecol Oncol 2012; 125 (01) 31-36
• 45 Dalal KM, Gollub MJ, Miner TJ. et al. Management of patients with malignant bowel obstruction and stage IV colorectal cancer. J Palliat Med 2011; 14 (07) 822-828
• 46 Pujara D, Chiang YJ, Cormier JN, Bruera E, Badgwell B. Selective approach for patients with advanced malignancy and gastrointestinal obstruction. J Am Coll Surg 2017; 225 (01) 53-59
• 47 Kawata N, Kakushima N, Tanaka M. et al. Percutaneous endoscopic gastrostomy for decompression of malignant bowel obstruction. Dig Endosc 2014; 26 (02) 208-213
• 48 Pothuri B, Montemarano M, Gerardi M. et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 2005; 96 (02) 330-334
• 49 Lowe AS, Beckett CG, Jowett S. et al. Self-expandable metal stent placement for the palliation of malignant gastroduodenal obstruction: experience in a large, single, UK centre. Clin Radiol 2007; 62 (08) 738-744
• 50 Telford JJ, Carr-Locke DL, Baron TH. et al. Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent: outcomes from a multicenter study. Gastrointest Endosc 2004; 60 (06) 916-920
• 51 Dormann A, Meisner S, Verin N, Wenk Lang A. Self-expanding metal stents for gastroduodenal malignancies: systematic review of their clinical effectiveness. Endoscopy 2004; 36 (06) 543-550
• 52 Nassif T, Prat F, Meduri B. et al. Endoscopic palliation of malignant gastric outlet obstruction using self-expandable metallic stents: results of a multicenter study. Endoscopy 2003; 35 (06) 483-489
• 53 Nagaraja V, Eslick GD, Cox MR. Endoscopic stenting versus operative gastrojejunostomy for malignant gastric outlet obstruction-a systematic review and meta-analysis of randomized and non-randomized trials. J Gastrointest Oncol 2014; 5 (02) 92-98
• 54 Upchurch E, Ragusa M, Cirocchi R. Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction. Cochrane Database Syst Rev 2018; 5: CD012506
• 55 Tyberg A, Karia K, Zerbo S, Sharaiha RZ, Kahaleh M. Endoscopic ultrasound-guided choledochojejunostomy with a lumen-apposing metal stent: a shortcut for biliary drainage. Endoscopy 2015; 47 (Suppl 1 UCTN): E342-E343
• 56 Itoi T, Ishii K, Ikeuchi N. et al. Prospective evaluation of endoscopic ultrasonography-guided double-balloon-occluded gastrojejunostomy bypass (EPASS) for malignant gastric outlet obstruction. Gut 2016; 65 (02) 193-195
• 57 Khot UP, Lang AW, Murali K, Parker MC. Systematic review of the efficacy and safety of colorectal stents. Br J Surg 2002; 89 (09) 1096-1102
• 58 Sebastian S, Johnston S, Geoghegan T, Torreggiani W, Buckley M. Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction. Am J Gastroenterol 2004; 99 (10) 2051-2057
• 59 Sagar J. Colorectal stents for the management of malignant colonic obstructions. Cochrane Database Syst Rev 2011; (11) CD007378
• 60 Kim JY, Kim SG, Im JP, Kim JS, Jung HC. Comparison of treatment outcomes of endoscopic stenting for colonic and extracolonic malignant obstruction. Surg Endosc 2013; 27 (01) 272-277
• 61 Moon SJ, Kim SW, Lee BI. et al. Palliative stent for malignant colonic obstruction by extracolonic malignancy: a comparison with colorectal cancer. Dig Dis Sci 2014; 59 (08) 1891-1897
• 62 Faraz S, Salem SB, Schattner M. et al. Predictors of clinical outcome of colonic stents in patients with malignant large-bowel obstruction because of extracolonic malignancy. Gastrointest Endosc 2018; 87 (05) 1310-1317
• 63 Brooksbank MA, Game PA, Ashby MA. Palliative venting gastrostomy in malignant intestinal obstruction. Palliat Med 2002; 16 (06) 520-526
• 64 Shaw C, Bassett RL, Fox PS. et al. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites. Ann Surg Oncol 2013; 20 (02) 497-505
• 65 O'Connor OJ, Diver E, McDermott S. et al. Palliative gastrostomy in the setting of voluminous ascites. J Palliat Med 2014; 17 (07) 811-821
• 66 Tamura A, Kato K, Suzuki M. et al. CT-guided percutaneous radiologic gastrostomy for patients with head and neck cancer: a retrospective evaluation in 177 patients. Cardiovasc Intervent Radiol 2016; 39 (02) 271-278
• 67 Jiang XY, Bertrand AS, Li G. et al. CT-guided percutaneous gastrostomy without preliminary placement of a nasogastric tube. J Vasc Interv Radiol 2019; 30 (06) 915-917
• 68 Burns KM, Huang SY. Percutaneous transesophageal gastric tubes: indications, technique, safety, efficacy, and management. Dig Dis Interv 2018; 2: 72-78
• 69 Aramaki T, Arai Y, Inaba Y. et al. Phase II study of percutaneous transesophageal gastrotubing for patients with malignant gastrointestinal obstruction; JIVROSG-0205. J Vasc Interv Radiol 2013; 24 (07) 1011-1017
• 70 Inoue M, Uchida K, Kawamoto A. et al. Percutaneous transesophageal gastrostomy (PTEG) placement in an infant. J Pediatr Gastroenterol Nutr 2007; 45 (03) 363-365
• 71 Toh Yoon EW, Nishihara K. Percutaneous transesophageal gastro-tubing (PTEG) as an alternative long-term tube feeding procedure when gastrostomy is not feasible. Therap Adv Gastroenterol 2017; 10 (12) 911-917
• 72 Mackey R, Chand B, Oishi H, Kameoka S, Ponsky JL. Percutaneous transesophageal gastrostomy tube for decompression of malignant obstruction: report of the first case and our series in the US. J Am Coll Surg 2005; 201 (05) 695-700
• 73 Pannala R, Brandabur JJ, Gan SI. et al. Afferent limb syndrome and delayed GI problems after pancreaticoduodenectomy for pancreatic cancer: single-center, 14-year experience. Gastrointest Endosc 2011; 74 (02) 295-302
• 74 Sato Y, Inaba Y, Murata S. et al. Percutaneous drainage for afferent limb syndrome and pancreatic fistula via the blind end of the jejunal limb after pancreatoduodenectomy or bile duct resection. J Vasc Interv Radiol 2015; 26 (04) 566-572
• 75 Baron TH. Interventional palliative strategies for malignant bowel obstruction. Curr Oncol Rep 2009; 11 (04) 293-297
• 76 Teriaky A, Gregor J, Chande N. Percutaneous endoscopic gastrostomy tube placement for end-stage palliation of malignant gastrointestinal obstructions. Saudi J Gastroenterol 2012; 18 (02) 95-98
• 77 Kim YJ, Yoon CJ, Seong NJ, Kang SG, An SW, Woo YN. Safety and efficacy of radiological percutaneous jejunostomy for decompression of malignant small bowel obstruction. Eur Radiol 2013; 23 (10) 2747-2753
• 78 Tewari SO, Getrajdman GI, Petre EN. et al. Safety and efficacy of percutaneous cecostomy/colostomy for treatment of large bowel obstruction in adults with cancer. J Vasc Interv Radiol 2015; 26 (02) 182-188
• 79 Saber A, Hokkam EN. Efficacy of protective tube cecostomy after restorative resection for colorectal cancer: a randomized trial. Int J Surg 2013; 11 (04) 350-353
• 80 Naghibi M, Smith TR, Elia M. A systematic review with meta-analysis of survival, quality of life and cost-effectiveness of home parenteral nutrition in patients with inoperable malignant bowel obstruction. Clin Nutr 2015; 34 (05) 825-837
• 81 Sowerbutts AM, Lal S, Sremanakova J. et al. Home parenteral nutrition for people with inoperable malignant bowel obstruction. Cochrane Database Syst Rev 2018; 8: CD012812
• 82 Duerksen DR, Ting E, Thomson P. et al. Is there a role for TPN in terminally ill patients with bowel obstruction?. Nutrition 2004; 20 (09) 760-763
• 83 August DA, Thorn D, Fisher RL, Welchek CM. Home parenteral nutrition for patients with inoperable malignant bowel obstruction. JPEN J Parenter Enteral Nutr 1991; 15 (03) 323-327
• 84 Chermesh I, Mashiach T, Amit A. et al. Home parenteral nutrition (HTPN) for incurable patients with cancer with gastrointestinal obstruction: do the benefits outweigh the risks?. Med Oncol 2011; 28 (01) 83-88
• 85 King LA, Carson LF, Konstantinides N. et al. Outcome assessment of home parenteral nutrition in patients with gynecologic malignancies: what have we learned in a decade of experience?. Gynecol Oncol 1993; 51 (03) 377-382
• 86 Mercadante S. Parenteral nutrition at home in advanced cancer patients. J Pain Symptom Manage 1995; 10 (06) 476-480
• 87 Pironi L, Ruggeri E, Tanneberger S, Giordani S, Pannuti F, Miglioli M. Home artificial nutrition in advanced cancer. J R Soc Med 1997; 90 (11) 597-603
• 88 Soo I, Gramlich L. Use of parenteral nutrition in patients with advanced cancer. Appl Physiol Nutr Metab 2008; 33 (01) 102-106
• 89 Dy SM. Enteral and parenteral nutrition in terminally ill cancer patients: a review of the literature. Am J Hosp Palliat Care 2006; 23 (05) 369-377
• 90 Cwikiel W. Percutaneous duodenostomy--alternative route for enteral nutrition. Acta Radiol 1991; 32 (02) 153-154
• 91 Turner JH, Wittich GR. Direct percutaneous transperitoneal duodenostomy: an alternative form of enteral feeding. AJR Am J Roentgenol 2001; 176 (01) 159-160
• 92 van Overhagen H, Ludviksson MA, Laméris JS. et al. US and fluoroscopic-guided percutaneous jejunostomy: experience in 49 patients. J Vasc Interv Radiol 2000; 11 (01) 101-106
• 93 Cope C, Davis AG, Baum RA, Haskal ZJ, Soulen MC, Shlansky-Goldberg RD. Direct percutaneous jejunostomy: techniques and applications--ten years experience. Radiology 1998; 209 (03) 747-754
• 94 Kim CY, Engstrom BI, Horvath JJ, Lungren MP, Suhocki PV, Smith TP. Comparison of primary jejunostomy tubes versus gastrojejunostomy tubes for percutaneous enteral nutrition. J Vasc Interv Radiol 2013; 24 (12) 1845-1852